Edition:
India

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

7.13USD
31 Jul 2020
Change (% chg)

$0.00 (+0.00%)
Prev Close
$7.13
Open
--
Day's High
--
Day's Low
--
Volume
400
Avg. Vol
615,642
52-wk High
$7.49
52-wk Low
$2.71

Select another date:

Tue, Jul 7 2020

BRIEF-Cerus Corp Reports Successful Inactivation Of Sars-Cov-2 With The Intercept Blood System For Plasma

* CERUS CORPORATION REPORTS SUCCESSFUL INACTIVATION OF SARS-COV-2 WITH THE INTERCEPT BLOOD SYSTEM FOR PLASMA

BRIEF-Cerus Corp Says Adopted Cerus Corp Executive Nonqualified Excess Plan

* CERUS CORP - ON MAY 21, ADOPTED CERUS CORPORATION EXECUTIVE NONQUALIFIED EXCESS PLAN

BRIEF-Cerus Corporation Announces FDA Pma Supplement Submission For Pathogen-Reduced Cryoprecipitated Fibrinogen Complex

* CERUS CORPORATION ANNOUNCES FDA PMA SUPPLEMENT SUBMISSION FOR PATHOGEN-REDUCED CRYOPRECIPITATED FIBRINOGEN COMPLEX

BRIEF-Cerus Corporation Announces First Quarter 2020 Results

* Q1 REVENUE $24.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $23.1 MILLION

BRIEF-Cerus Corporation Announces FDA Approval For Intercept Blood System

* CERUS CORPORATION ANNOUNCES FDA APPROVAL FOR INTERCEPT BLOOD SYSTEM FOR PLASMA WITH ALTERNATE PLASTIC DISPOSABLE KITS Source text for Eikon: Further company coverage:

BRIEF-Cerus Announces Expansion Of BARDA Funding To Support Development Of Intercept Blood System For RBCs

* CERUS CORPORATION ANNOUNCES EXPANSION OF BARDA FUNDING TO SUPPORT DEVELOPMENT OF INTERCEPT BLOOD SYSTEM FOR RED BLOOD CELLS

BRIEF-Cerus Corporation Provides Update On Covid-19 Related Activities

* CERUS CORPORATION PROVIDES UPDATE ON COVID-19 RELATED ACTIVITIES

BRIEF-Cerus Corporation Announces The Inclusion Of Pathogen Reduction Technology In The ISBT Working Party Recommendations For The Preparation Of COVID-19 Convalescent Plasma

* CERUS CORPORATION ANNOUNCES THE INCLUSION OF PATHOGEN REDUCTION TECHNOLOGY IN THE ISBT WORKING PARTY RECOMMENDATIONS FOR THE PREPARATION OF COVID-19 CONVALESCENT PLASMA Source text for Eikon: Further company coverage:

BRIEF-Cerus Posts Quarterly Loss Per Share Of $0.12

* ORATION ANNOUNCES RECORD FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS

BRIEF-U.S. Department Of Defense Awards Funding For Study To Evaluate The Use Of Intercept Plasma In Traumatic Burn Resuscitation

* U.S. DEPARTMENT OF DEFENSE AWARDS FUNDING FOR STUDY TO EVALUATE THE USE OF INTERCEPT PLASMA IN TRAUMATIC BURN RESUSCITATION

Select another date: